Monovalent single-chain Fv fragments and bivalent mini antibodies bound to vesicular stomatitis virus protect against lethal infection

被引:36
作者
Kalinke, U
Krebber, A
Krebber, C
Bucher, E
Pluckthun, A
Zinkernagel, RM
Hengartner, H
机构
[1] UNIV ZURICH,INST BIOCHEM,CH-8057 ZURICH,SWITZERLAND
[2] UNIV ZURICH,INST EXPT IMMUNOL,DEPT PATHOL,CH-8091 ZURICH,SWITZERLAND
关键词
vesicular stomatitis virus; virus neutralization; single-chain Fv;
D O I
10.1002/eji.1830261202
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Several antibody-dependent mechanisms have been postulated to mediate neutralization of different animal viruses, including blocking of docking to receptors, induction of conformational changes in the virus coat, and Fc-dependent opsonization. We have studied the molecular requirements for antibody-mediated neutralization of vesicular stomatitis virus (VSV) in vitro and protection against lethal disease in vivo with a single-chain Fv fragment (scFv) and the corresponding bivalent miniantibody (scFv-dHLX) generated from a VSV-neutralizing monoclonal antibody. Both monovalent scFv and bivalent scFv-dHLX miniantibodies were able to neutralize VSV in vitro and to protect interferon-alpha beta receptor-deficient (IFN-alpha beta R(-/-)) mice against lethal disease after intravenous injection of 50 plaque-forming units (pfu) VSV pre-incubated with the scFv reagents. Similarly, severe-combined immunodeficient (SCID) mice infected with immune complexes of 10(8) pfu VSV and bivalent scFv-dHLX were protected against lethal disease; however, mice infected with immune complexes of 10(8) pfu VSV and monovalent scFv were not. Although repeated scFv-dHLX treatment reduced virus quantities in the blood, neither SCID nor IFN-alpha beta R(-/-) mice were protected against lethal disease after passive immunization and subsequent VSV infection. This was due to the short half-life of 17 min of scFv-dHLX in the circulation. These data demonstrate that neutralization of VSV and protection against lethal disease do not require Fc-mediated mechanisms and that cross-linking is not crucial for protection against physiologically relevant virus doses in vivo.
引用
收藏
页码:2801 / 2806
页数:6
相关论文
共 31 条
[1]  
BACHMANN MF, 1994, J IMMUNOL, V152, P4235
[2]   MODEL IN MICE FOR PATHOGENESIS AND TREATMENT OF RABIES [J].
BAER, GM ;
CLEARY, WF .
JOURNAL OF INFECTIOUS DISEASES, 1972, 125 (05) :520-&
[3]   HUMAN MONOCLONAL FAB FRAGMENTS DERIVED FROM A COMBINATORIAL LIBRARY BIND TO RESPIRATORY SYNCYTIAL VIRUS-F GLYCOPROTEIN AND NEUTRALIZE INFECTIVITY [J].
BARBAS, CF ;
CROWE, JE ;
CABABA, D ;
JONES, TM ;
ZEBEDEE, SL ;
MURPHY, BR ;
CHANOCK, RM ;
BURTON, DR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (21) :10164-10168
[4]   MECHANISMS OF MONOCLONAL ANTIBODY-MEDIATED PROTECTION AGAINST VIRULENT SEMLIKI FOREST VIRUS [J].
BOERE, WAM ;
BENAISSATROUW, BJ ;
HARMSEN, T ;
ERICH, T ;
KRAAIJEVELD, CA ;
SNIPPE, H .
JOURNAL OF VIROLOGY, 1985, 54 (02) :546-551
[5]  
CHARAN S, 1986, J IMMUNOL, V136, P3057
[6]   A RECOMBINANT HUMAN FAB EXPRESSED IN ESCHERICHIA-COLI NEUTRALIZES RABIES VIRUS [J].
CHEUNG, SC ;
DIETZSCHOLD, B ;
KOPROWSKI, H ;
NOTKINS, AL ;
RANDO, RF .
JOURNAL OF VIROLOGY, 1992, 66 (11) :6714-6720
[7]   HUMANIZED ANTIBODIES FOR ANTIVIRAL THERAPY [J].
CO, MS ;
DESCHAMPS, M ;
WHITLEY, RJ ;
QUEEN, C .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (07) :2869-2873
[8]   RECOMBINANT HUMAN RESPIRATORY SYNCYTIAL VIRUS (RSV) MONOCLONAL-ANTIBODY FAB IS EFFECTIVE THERAPEUTICALLY WHEN INTRODUCED DIRECTLY INTO THE LUNGS OF RSV-INFECTED MICE [J].
CROWE, JE ;
MURPHY, BR ;
CHANOCK, RM ;
WILLIAMSON, RA ;
BARBAS, CF ;
BURTON, DR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (04) :1386-1390
[9]  
DIMMOCK NJ, 1993, NEUTRALIZATION ANIMA, P74
[10]   ENGINEERED ANTIBODIES AS PHARMACOLOGICAL TOOLS [J].
HABER, E .
IMMUNOLOGICAL REVIEWS, 1992, 130 :189-212